SCHEMBL7002196

SCHEMBL7002196

CCOC(=O)c1c(Nc2c(N)ccc(Cl)c2Cl)sc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
TP53 P04637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
GRM6 O15303 3/20 0.43
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
MEN1 O00255 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPK1 P28482 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
METTL3 Q86U44 1/20 0.40
RPS6KB1 P23443 1/20 0.40
CDK2 P24941 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
GSK3B P49841 1/20 0.40
RPS6KA3 P51812 1/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6995841 0.84 MAPT (0.41) MAPTTP53RXFP1ALDH1A1KMT2A
SCHEMBL6997161 0.82 MAPT (0.44) MAPTTP53RXFP1GRM6ALDH1A1
SCHEMBL6996720 0.81 MAPT (0.44) MAPTTP53RXFP1GRM6ALDH1A1
SCHEMBL6994066 0.80 SMN1; SMN2 (0.54) MAPTGRM6ALDH1A1KMT2ACYP1A2
SCHEMBL6997271 0.79 MAPT (0.44) MAPTTP53RXFP1GRM6ALDH1A1
SCHEMBL6996750 0.79 SMN1; SMN2 (0.45) MAPTGRM6ALDH1A1KMT2ACYP1A2
SCHEMBL7699031 0.77 ILK (0.53) MAPTTP53RXFP1ALDH1A1KMT2A
SCHEMBL6991553 0.77 SMN1; SMN2 (0.43) MAPTALDH1A1KMT2ACYP1A2CYP2C9
SCHEMBL6993864 0.77 SMN1; SMN2 (0.43) MAPTGRM6ALDH1A1CYP1A2CYP2C9
SCHEMBL6998866 0.77 CISD2 (0.45) MAPTGRM6ALDH1A1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885TP53 414/4885RXFP1 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.